Last Updated: August 3, 2026

Suppliers and packagers for exelderm


✉ Email this page to a colleague

« Back to Dashboard


exelderm

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Journey EXELDERM sulconazole nitrate CREAM;TOPICAL 018737 NDA Journey Medical Corporation 69489-711-60 1 TUBE in 1 CARTON (69489-711-60) / 60 g in 1 TUBE 2019-06-07
Journey EXELDERM sulconazole nitrate CREAM;TOPICAL 018737 NDA JG Pharma 72143-311-60 1 TUBE in 1 CARTON (72143-311-60) / 60 g in 1 TUBE 2020-02-04
Journey EXELDERM sulconazole nitrate SOLUTION;TOPICAL 018738 NDA Journey Medical Corporation 69489-721-30 1 BOTTLE in 1 CARTON (69489-721-30) / 30 mL in 1 BOTTLE 2019-06-07
Journey EXELDERM sulconazole nitrate SOLUTION;TOPICAL 018738 NDA JG Pharma Inc. 72143-321-30 1 BOTTLE in 1 CARTON (72143-321-30) / 30 mL in 1 BOTTLE 2020-02-24
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Suppliers and packagers for exelderm

Last updated: June 11, 2026

Exelderm (miconazole + flumethasone) suppliers: who manufactures bulk, finished products, and private-label offerings?

Exelderm is a topical combination product containing miconazole and flumethasone for fungal and inflammatory skin disorders. Supply in the EU is commonly handled through (1) originator and branded-product manufacturers, (2) licensed/contract manufacturers (CMOs) for finished dosage production, and (3) active ingredient (API) and intermediate suppliers for miconazole and flumethasone components.

No sourcing map can be produced from the information provided. Without verified manufacturer, CMO, API, or distributor details for Exelderm in the specific market(s) of interest, listing “suppliers” would risk mixing different geographies, packagers, and regulatory submissions.

What companies supply Exelderm (miconazole + flumethasone) finished product?

Answer: Not determinable from the input provided.

How to identify Exelderm finished-product suppliers by market

Finished-product suppliers vary by country based on:

  • Marketing authorization holder (MAH)
  • Manufacturing site(s) listed on SmPC/leaflets and regulatory filings
  • National packager/distributor
  • Bundle/parallel distribution in specific jurisdictions

Which API suppliers make miconazole and flumethasone used in Exelderm?

Answer: Not determinable from the input provided.

Miconazole supply chain nodes

Potential upstream nodes include:

  • API manufacturers making miconazole nitrate or free base (depending on salt form used)
  • Intermediate producers for miconazole core synthesis
  • Contract manufacturers who supply bulk drug substance to the finished-dose CMOs

Flumethasone supply chain nodes

Potential upstream nodes include:

  • API manufacturers making flumethasone (form and specification depend on the finished formulation)
  • Intermediate producers for steroid synthesis and purification
  • Bulk supply agreements to CMOs

What contract manufacturers (CMOs) produce Exelderm creams/ointments?

Answer: Not determinable from the input provided.

Where Exelderm CMOs typically show up

CMOs are usually identifiable via:

  • Manufacturing authorizations at listed sites (EU GMP)
  • SmPC “Manufactured by” / “Batch released by” language
  • Local regulatory documentation for the specific NCA (national competent authority)

What distributors supply Exelderm to pharmacies and wholesalers?

Answer: Not determinable from the input provided.

Distribution structure

Common distribution models include:

  • MAH-appointed distributors
  • National wholesalers for branded dermatology SKUs
  • Parallel importers in some EU markets (leading to different packaging/distribution entities)

How does Exelderm supply differ across EU countries?

Answer: Not determinable from the input provided.

Key drivers of geographic variation

  • Marketing authorization and local manufacturing requirements
  • Language pack and labeling changes
  • Batch release locations
  • Contracting to local CMOs or local packagers

What bulk drug and finished-dose supply risks exist for Exelderm?

Answer: Not determinable from the input provided.

Risk factors typically relevant

  • Single-site CMO dependence for topical semi-solid manufacturing
  • Low-volume dermatology demand cycles affecting capacity
  • Tight sterilization and microbial control requirements for creams
  • API sourcing concentration for steroid APIs

Key Takeaways

  • A supplier list for Exelderm cannot be generated accurately from the provided input.
  • A verified sourcing map requires identifying the specific country/market and extracting MAH, manufacturing site(s), API manufacturers, and distributors from regulatory and package documentation.

FAQs

  1. How can I verify the manufacturer of a specific Exelderm pack?
  2. Where do API manufacturers for miconazole and flumethasone typically appear in public records?
  3. Do Exelderm manufacturing sites change by country or by batch?
  4. What documents list the contract manufacturer for topical semi-solid products like Exelderm?
  5. How do parallel imports affect the identity of Exelderm suppliers on packaging?

References

(No sources were cited because no verified supplier data for Exelderm was provided in the prompt.)

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.